Rapport Therapeutics Common StockNASDAQ: RAPP

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Rapport Therapeutics Common Stock is in the Healthcare sector

Rapport Therapeutics Common Stock is in the Biotechnology industry

Rapport Therapeutics Common Stock is headquartered in United States

https://www.rapportrx.com

No, Rapport Therapeutics Common Stock is not included in the S&P 500 index

No, Rapport Therapeutics Common Stock is not included in the NASDAQ 100 index

No, Rapport Therapeutics Common Stock is not included in the Dow Jones index

The next expected earnings date for Rapport Therapeutics Common Stock is 30 August 2024